Esther S Oh1, Jeannie-Marie Leoutsakos2, Paul B Rosenberg2, Alexandra M Pletnikova3, Harpal S Khanuja4, Robert S Sterling4, Julius K Oni4, Frederick E Sieber5, Neal S Fedarko3, Narjes Akhlaghi3, Karin J Neufeld6. 1. Departments of Medicine (ESO, AP, NSF, NA), Johns Hopkins University School of Medicine, Baltimore, MD; Departments of Psychiatry and Behavioral Sciences (ESO, JML, PBR, KJN), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Pathology (ESO), Johns Hopkins University School of Medicine, Baltimore, MD; Johns Hopkins University School of Nursing (ESO, KJN), Baltimore, MD. Electronic address: eoh9@jhmi.edu. 2. Departments of Psychiatry and Behavioral Sciences (ESO, JML, PBR, KJN), Johns Hopkins University School of Medicine, Baltimore, MD. 3. Departments of Medicine (ESO, AP, NSF, NA), Johns Hopkins University School of Medicine, Baltimore, MD. 4. Departments of Orthopedic Surgery (HSK, RSS, JKO), Johns Hopkins University School of Medicine, Baltimore, MD. 5. Departments of Anesthesiology and Critical Care Medicine (FES), Johns Hopkins University School of Medicine, Baltimore, MD. 6. Departments of Psychiatry and Behavioral Sciences (ESO, JML, PBR, KJN), Johns Hopkins University School of Medicine, Baltimore, MD; Johns Hopkins University School of Nursing (ESO, KJN), Baltimore, MD.
Abstract
OBJECTIVES: Postoperative delirium, associated with negative consequences including longer hospital stays and worse cognitive and physical outcomes, is frequently accompanied by sleep-wake disturbance. Our objective was to evaluate the efficacy and short-term safety of ramelteon, a melatonin receptor agonist, for the prevention of postoperative delirium in older patients undergoing orthopedic surgery. DESIGN: A quadruple-masked randomized placebo-controlled trial (Clinical Trials.gov NCT02324153) conducted from March 2017 to June 2019. SETTING: Tertiary academic medical center. PARTICIPANTS: Patients aged 65 years or older, undergoing elective primary or revision hip or knee replacement. INTERVENTION: Ramelteon (8 mg) or placebo MEASUREMENTS: Eighty participants were randomized to an oral gel cap of ramelteon or placebo for 3 consecutive nights starting the night before surgery. Trained research staff conducted delirium assessments for 3 consecutive days starting on postoperative day (POD) 0, after recovery from anesthesia, and on to POD2. A delirium diagnosis was based upon DSM-5 criteria determined by expert panel consensus. RESULTS: Of 80 participants, five withdrew consent (one placebo, four ramelteon) and four were excluded (four ramelteon) after randomization. Delirium incidence during the 2 days following surgery was 7% (5 of 71) with no difference between the ramelteon versus placebo: 9% (3 of 33) and 5% (2 of 38), respectively. The adjusted odds ratio for postoperative delirium as a function of assignment to the ramelteon treatment arm was 1.28 (95% confidence interval: 0.21-7.93; z-value 0.27; p-value = 0.79). Adverse events were similar between the two groups. CONCLUSION: In older patients undergoing elective primary or revision hip or knee replacement, ramelteon was not efficacious in preventing postoperative delirium.
OBJECTIVES: Postoperative delirium, associated with negative consequences including longer hospital stays and worse cognitive and physical outcomes, is frequently accompanied by sleep-wake disturbance. Our objective was to evaluate the efficacy and short-term safety of ramelteon, a melatonin receptor agonist, for the prevention of postoperative delirium in older patients undergoing orthopedic surgery. DESIGN: A quadruple-masked randomized placebo-controlled trial (Clinical Trials.gov NCT02324153) conducted from March 2017 to June 2019. SETTING: Tertiary academic medical center. PARTICIPANTS: Patients aged 65 years or older, undergoing elective primary or revision hip or knee replacement. INTERVENTION: Ramelteon (8 mg) or placebo MEASUREMENTS: Eighty participants were randomized to an oral gel cap of ramelteon or placebo for 3 consecutive nights starting the night before surgery. Trained research staff conducted delirium assessments for 3 consecutive days starting on postoperative day (POD) 0, after recovery from anesthesia, and on to POD2. A delirium diagnosis was based upon DSM-5 criteria determined by expert panel consensus. RESULTS: Of 80 participants, five withdrew consent (one placebo, four ramelteon) and four were excluded (four ramelteon) after randomization. Delirium incidence during the 2 days following surgery was 7% (5 of 71) with no difference between the ramelteon versus placebo: 9% (3 of 33) and 5% (2 of 38), respectively. The adjusted odds ratio for postoperative delirium as a function of assignment to the ramelteon treatment arm was 1.28 (95% confidence interval: 0.21-7.93; z-value 0.27; p-value = 0.79). Adverse events were similar between the two groups. CONCLUSION: In older patients undergoing elective primary or revision hip or knee replacement, ramelteon was not efficacious in preventing postoperative delirium.
Authors: Stuti J Jaiswal; Anuja D Vyas; Andrew J Heisel; Haritha Ackula; Ashna Aggarwal; Nick H Kim; Kim M Kerr; Michael Madani; Victor Pretorius; William R Auger; Timothy M Fernandes; Atul Malhotra; Robert L Owens Journal: Crit Care Med Date: 2019-12 Impact factor: 7.598
Authors: Annemarieke de Jonghe; Barbara C van Munster; J Carel Goslings; Peter Kloen; Carolien van Rees; Reinder Wolvius; Romuald van Velde; Marcel Levi; Rob J de Haan; Sophia E de Rooij Journal: CMAJ Date: 2014-09-02 Impact factor: 8.262
Authors: Troy S Wildes; Angela M Mickle; Arbi Ben Abdallah; Hannah R Maybrier; Jordan Oberhaus; Thaddeus P Budelier; Alex Kronzer; Sherry L McKinnon; Daniel Park; Brian A Torres; Thomas J Graetz; Daniel A Emmert; Ben J Palanca; Shreya Goswami; Katherine Jordan; Nan Lin; Bradley A Fritz; Tracey W Stevens; Eric Jacobsohn; Eva M Schmitt; Sharon K Inouye; Susan Stark; Eric J Lenze; Michael S Avidan Journal: JAMA Date: 2019-02-05 Impact factor: 56.272
Authors: Joost Witlox; Lisa S M Eurelings; Jos F M de Jonghe; Kees J Kalisvaart; Piet Eikelenboom; Willem A van Gool Journal: JAMA Date: 2010-07-28 Impact factor: 56.272
Authors: Daniel J Buysse; Martica L Hall; Patrick J Strollo; Thomas W Kamarck; Jane Owens; Laisze Lee; Steven E Reis; Karen A Matthews Journal: J Clin Sleep Med Date: 2008-12-15 Impact factor: 4.062
Authors: Tamara G Fong; Sarinnapha M Vasunilashorn; Yun Gou; Towia A Libermann; Simon Dillon; Eva Schmitt; Steven E Arnold; Pia Kivisäkk; Becky Carlyle; Esther S Oh; Kamen Vlassakov; Lisa Kunze; Tammy Hshieh; Richard N Jones; Edward R Marcantonio; Sharon K Inouye Journal: Alzheimers Dement (N Y) Date: 2021-03-17